UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 8, 2009

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number including area code: (410) 269-2600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01                                            Regulation FD Disclosure

On December 8, 2009, PharmAthene, Inc. (the “Company”) issued a press release announcing that the time for the conference call to provide an update on its recombinant protective antigen anthrax vaccine program has been changed to Wednesday, December 9, 2009 at 9.00 a.m. Eastern Time.  A copy of the press release, containing instructions on how to access the call, is furnished as Exhibit 99.1 to this report.

In accordance with General Instruction B.2. of Form 8-K, the information included in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01                                            Financial Statements and Exhibits

(d) Exhibits

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3

Exhibit 99.1

Contact:

Stacey Jurchison

PharmAthene, Inc.

Phone: 410-269-2610

Cell: 410-474-8200

Stacey.Jurchison@PharmAthene.com

FOR IMMEDIATE RELEASE

PHARMATHENE ANNOUNCES UPDATED TIME FOR CONFERENCE CALL TO REVIEW BARDA rPA DECISION

Call Scheduled for 9:00 a.m. Eastern Time, Wednesday, December 9, 2009

ANNAPOLIS, MD – December 8, 2009 — PharmAthene, Inc. (NYSE Amex: PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it will hold a conference call at 9:00 a.m. Eastern Time, on Wednesday, December 9, 2009 to provide an update on its recombinant protective antigen (rPA) anthrax vaccine program.  The dial-in number for U.S. callers is 866-383-8108 and for international callers is 617-597-5343.  The participant passcode is 50815141.

A replay of the conference call will be available beginning at approximately 1:00 pm. Eastern Time on December 9, 2009 until approximately 11:59 p.m. Eastern Time January 9, 2010. The dial-in number from within the United States is 888-286-8010.  For international callers, the dial-in number is 617-801-6888.  The participant passcode is 67021476.

The webcast of the conference call will be available until January 9, 2010 and can be accessed from the company’s website at http://www.pharmathene.com. A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene’s lead product development programs include:

·                  SparVax™ — a second generation recombinant protective antigen (rPA) anthrax vaccine

·                  Third generation rPA anthrax vaccine

·                  Valortim®— a fully human monoclonal antibody for the prevention and treatment of anthrax infection

1

·                  Protexia® — a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

·                  RypVax™ — a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

###

2